- active not recruitingPHASE1
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
This study is testing a new medicine, IMA401, for people with advanced cancers that have come back or haven't responded to other treatments. We want to see if it's safe, how well people tolerate it, and if it can help shrink tumours, either alone or with another cancer drug called pembrolizumab.
Germany - recruitingPHASE1, PHASE2
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
This study is testing a new medicine, IMA402, for adults with advanced or returning solid cancers that haven't responded to other treatments. We want to see if it's safe, what dose works best, and if it can help shrink tumours.
Germany · Netherlands - recruitingPHASE1, PHASE2
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
This study looks at new ways to treat cancer in children and teenagers (up to 21 years old). It uses information from a patient's cancer cells to choose the best medicines, aiming for more personalised and effective treatments.
Australia · Canada - recruitingPHASE1, PHASE2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
This study looks at a new drug, BGB-16673, combined with other medicines for people with B-cell cancers that have come back or not responded to past treatments. It checks how safe and effective these combinations are.
United States · Australia · Brazil - recruitingPHASE4
Plan Development for Giving Teclistamab in the Outpatient Setting
This study is looking at how to give a cancer medicine called teclistamab to people with multiple myeloma at home or at an outpatient clinic. It also wants to understand how this affects their caregivers.
Canada - active not recruitingPHASE1, PHASE2
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
This study is looking at a new medicine called HST-1011, sometimes with another medicine called cemiplimab, for adults with advanced solid cancers. It's for people whose cancer hasn't responded to previous treatments or has come back after them.
United States · Canada · Spain